Generate Biomedicines Quarterly Cash Flow Statement
NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Generate Biomedicines free cash flow
In the quarter ended Jun 30, 2026, Generate Biomedicines generated -$57.9 million of operating cash flow and spent $933,000 on capital expenditures. That left free cash flow of -$58.9 million, a free-cash-flow margin of -932.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Generate Biomedicines cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -67.25M | -61.71M | -56.74M | -44.31M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 3.20M | 3.27M | 3.30M | 3.41M |
| Stock-Based Compensation | 8.24M | 6.39M | 5.49M | 4.74M |
| Change in Working Capital | -8.42M | -22.47M | -912.00K | -14.51M |
| Operating Cash Flow | -57.94M | -80.39M | -48.75M | -53.18M |
| Capital Expenditures | -933.00K | -3.78M | -154.00K | -751.00K |
| Investing Cash Flow | 33.31M | -259.93M | -17.07M | 75.53M |
| Financing Cash Flow | -579.00K | 378.89M | -263.00K | 20.56M |
| Net Change in Cash | -25.21M | 38.57M | -66.08M | 42.92M |
| Free Cash Flow | -58.88M | -84.17M | -48.91M | -53.93M |
This table shows 4 quarterly periods of Generate Biomedicines's cash flow statement, from Q2 2026 back to Q? 2025, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GENB's reporting calendar. What is a cash flow statement?